LUYE PHARMA GROUP LTD.

绿叶制药集团有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 02186)

VOLUNTARY ANNOUNCEMENT

RIVASTIGMINE TWICE WEEKLY TRANSDERMAL PATCH APPROVED FOR MARKETING IN JAPAN

The board of directors (the "**Board**") of Luye Pharma Group Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") announces that the Group's independently developed innovative formulation, the Rivastigmine Twice Weekly Transdermal Patch, has been approved for marketing by the Ministry of Health, Labour and Welfare of Japan as a new drug for suppression of the progression of dementia symptoms in mild to moderate Alzheimer's disease. The product is to be marketed as Rivaluen® LA Patch 25.92 mg/51.84 mg. It is the first extended-release Rivastigmine transdermal patch product approved for marketing in Japan.

Developed by the Group on its proprietary platform for transdermal patches, Rivaluen® LA Patch 25.92 mg/51.84 mg employs an innovative drug delivery system to administer the active ingredient, rivastigmine, transdermally twice a week. The approval of this product is based on the positive results from a Phase III clinical trial conducted in Japan for treatment of patients with Alzheimer's type dementia. The clinical study has achieved its primary efficacy endpoint.

Alzheimer's disease is a neurodegenerative disease that causes a progressive decline in memory and other cognitive abilities. It is the most common type of dementia, accounting for 50%-75% of all cases. According to statistics, more than 55 million people worldwide suffer from dementia, with over 5 million in Japan. More than 50% of Japan's elderly population is at lifetime risk of developing dementia, with more than half of these cases are caused by Alzheimer's disease.

One of the early symptoms of Alzheimer's type dementia is said to be a decline in the ability to manage medication, and the choice of orally disintegrating tablets or patches has been suggested as a way to improve adherence. Compared to the commercially available once-daily rivastigmine transdermal patch, the Rivastigmine Twice Weekly Transdermal Patch requires a lower application frequency, which helps to improve patients' medication adherence. Additionally, compared to oral formulations, the transdermal administration method of this medication provides convenience for patients with swallowing difficulties, and has the potential to reduce the incidence of gastrointestinal adverse reactions such as nausea and vomiting.

To expedite the availability of this innovative treatment for Japanese patients, the Group entered into an agreement with Towa Pharmaceutical Co., Ltd. ("**Towa**") in December 2020, granting the latter an exclusive license for the development and commercialization of the Rivastigmine Twice Weekly Transdermal Patch in the Japanese market. Established in 1951, Towa is a prominent pharmaceutical company in Japan with multiple products in the central nervous system therapeutic field and strong commercial capabilities and a robust operational system in Japan. The Group looks forward to maintaining close collaboration with Towa to jointly deliver high-quality, innovative drugs as well as services and technologies to those in need.

In addition to the Japanese market, the Rivastigmine Twice Weekly Transdermal Patch has been approved for marketing in multiple European countries and China. Furthermore, the Group is also registering the product with local partners in selected countries of Southeast Asia and Latin America.

PRODUCT OVERVIEW OF THE RIVASTIGMINE TWICE WEEKLY TRANSDERMAL PATCH FOR THE JAPANESE MARKET

Product name	RIVALUEN® LA Patch 25.92 mg RIVALUEN® LA Patch 51.84 mg
Non-proprietary name	Rivastigmine
Indication or efficacy	Suppression of progression of dementia symptoms in mild to moderate Alzheimer's disease
Dosage and administration	In general, for adults, administer 25.92 mg of Rivastigmine as a starting dose. Increase to 51.84 mg as a maintenance dose four weeks later in principle. Apply the patch to normal healthy skin on the back, upper arm, or chest. In principle, apply a patch for four days at start and replace the patch every three or four days (twice weekly).

By Order of the Board
LUYE PHARMA GROUP LTD.
Liu Dian Bo
Chairman

Hong Kong, 31 March 2025

As at the date of this announcement, the executive directors of the Company are Mr. LIU Dian Bo, Mr. YANG Rong Bing, Mr. YUAN Hui Xian and Ms. ZHU Yuan Yuan; the non-executive directors of the Company are Mr. SONG Rui Lin and Mr. HUANG Liming; and the independent non-executive directors of the Company are Mr. ZHANG Hua Qiao, Professor LO Yuk Lam, Mr. LEUNG Man Kit, Mr. CHOY Sze Chung Jojo and Ms. XIA Lian.